State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee

IF 11.6 1区医学 Q1 HEMATOLOGY

Blood Cancer Journal Pub Date : 2025-08-29 DOI:10.1038/s41408-025-01341-6

Christine E. Ryan, Inhye E. Ahn, Aswin Sekar, Andrew Rawstron, Julia Almeida, Iñaki Martin-Subero, Erin M. Parry, Miguel Alcoceba, Dinis P. Calado, Alberto Orfao, Anton W. Langerak, Hendrik Veelken, Petra Langerbeins, Deborah M. Stephens, Sameer A. Parikh, Carsten U. Niemann, Sandrine Roulland, Kostas Stamatopoulos, Susan L. Slager, Tait Shanafelt, Paolo Ghia, Jessica Okosun, Matthew S. Davids

{"title":"State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee","authors":"Christine E. Ryan, Inhye E. Ahn, Aswin Sekar, Andrew Rawstron, Julia Almeida, Iñaki Martin-Subero, Erin M. Parry, Miguel Alcoceba, Dinis P. Calado, Alberto Orfao, Anton W. Langerak, Hendrik Veelken, Petra Langerbeins, Deborah M. Stephens, Sameer A. Parikh, Carsten U. Niemann, Sandrine Roulland, Kostas Stamatopoulos, Susan L. Slager, Tait Shanafelt, Paolo Ghia, Jessica Okosun, Matthew S. Davids","doi":"10.1038/s41408-025-01341-6","DOIUrl":null,"url":null,"abstract":"<p>In March 2023 and 2024, a panel of international experts convened at the first and second Intercepting Blood Cancers (IBC) Workshops, with the aim of better appreciating the diagnostic challenges, pathophysiology, and potential therapeutic interventions for precursor malignant hematology conditions. Here, we report a summary of the proceedings from the sessions focused on monoclonal B-cell lymphocytosis (MBL)/chronic lymphocytic leukemia (CLL). We highlight four main content areas: biology of MBL, clinical implications of MBL, progression of MBL and transformation from indolent CLL to aggressive disease, and opportunities for therapeutic intervention in early CLL. We additionally outline key consensus management recommendations and research goals.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"35 1","pages":""},"PeriodicalIF":11.6000,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Cancer Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41408-025-01341-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

In March 2023 and 2024, a panel of international experts convened at the first and second Intercepting Blood Cancers (IBC) Workshops, with the aim of better appreciating the diagnostic challenges, pathophysiology, and potential therapeutic interventions for precursor malignant hematology conditions. Here, we report a summary of the proceedings from the sessions focused on monoclonal B-cell lymphocytosis (MBL)/chronic lymphocytic leukemia (CLL). We highlight four main content areas: biology of MBL, clinical implications of MBL, progression of MBL and transformation from indolent CLL to aggressive disease, and opportunities for therapeutic intervention in early CLL. We additionally outline key consensus management recommendations and research goals.

Abstract Image

查看原文本刊更多论文

单克隆b细胞淋巴细胞增多症（MBL）的生物学、进展和临床管理的最新进展：拦截血癌研讨会委员会的共识报告

2023年3月和2024年3月，国际专家小组在第一届和第二届拦截血癌（IBC）研讨会上召开了会议，目的是更好地了解前体恶性血液病的诊断挑战、病理生理学和潜在的治疗干预措施。在这里，我们报告了一份关于单克隆b细胞淋巴细胞增多症(MBL)/慢性淋巴细胞白血病（CLL）会议的总结。我们强调了四个主要内容领域：MBL的生物学，MBL的临床意义，MBL的进展和从惰性CLL到侵袭性疾病的转变，以及早期CLL治疗干预的机会。我们还概述了关键共识管理建议和研究目标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Cancer Journal ONCOLOGY-

CiteScore

16.70

自引率

2.30%

发文量

153

审稿时长

>12 weeks

期刊介绍： Blood Cancer Journal is dedicated to publishing high-quality articles related to hematologic malignancies and related disorders. The journal welcomes submissions of original research, reviews, guidelines, and letters that are deemed to have a significant impact in the field. While the journal covers a wide range of topics, it particularly focuses on areas such as: Preclinical studies of new compounds, especially those that provide mechanistic insights Clinical trials and observations Reviews related to new drugs and current management of hematologic malignancies Novel observations related to new mutations, molecular pathways, and tumor genomics Blood Cancer Journal offers a forum for expedited publication of novel observations regarding new mutations or altered pathways.